Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Russia has released the first batch of COVID-19 vaccine, called Sputnik V, into civil movement and the supplies of the medication to the Russian regions are expected soon, said a report citing Russian Health Ministry.
The Russian health ministry enrolled the first vaccine against COVID-19, developed by Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), on August 11.
The first batch of the’Gam-COVID-Vac’ (Sputnik V) vaccine for the prevention of the new coronavirus infection has passed the necessary quality tests in the labs of Roszdravnadzor (medical device regulator) and has been introduced into civil circulation, the ministry was quoted as saying in an ANI report.
The ministry further said that the delivery of the first batch of this COVID-19 vaccine to the nation’s areas is projected in the nearest future, said the report.
Formerly Russian Health Minister Mikhail Murashko clarified that civilian production at this point meant vaccination of citizens from the risk groups, namely teachers and doctors, which will be carried out concurrently with post-registration clinical trials, reported Russian news agency TASS reported.
On September 4, Russian scientists belatedly released first results from early trials in the Sputnik V vaccine, which drew considerable criticism from experts, as the shots had just been tested on several dozen people before being more widely researched.
In a report published in the journal Lancet, developers of the vaccine stated it seemed to be safe and to prompt an antibody response in all 40 people tested in the second stage of the study within fourteen days.
1 part of the security trial included only men and the analysis mostly involved people in their 20s and 30s, so it is unclear how the vaccine might work in older populations most at risk of the more severe complications of COVID-19.
Meanwhile, Russia is also set to finish early-stage trials on a second potential COVID-19 vaccine created by the Vector Institute on September 30, the RIA news agency cited Russia’s consumer health security watchdog as saying.
